Experts: No Robust Evidence of ADHD Overdiagnosis in the UK

Experts writing in a paper describe a UK debate that has increasingly suggested ADHD may be overdiagnosed, and they report that published evidence does not support claims of widespread overdiagnosis in the UK.

The authors say this narrative can overshadow a more pressing concern—persistent unmet need for timely assessment, support, and treatment—amid rising demand and stretched services. They characterize the public conversation as one that can distract from gaps in identification and care pathways rather than clarifying them. Overall, the paper’s framing emphasizes under-detection and constrained service capacity rather than systematic over-identification.

With standardized diagnostic criteria applied, the authors report international prevalence estimates of approximately 5.4% in those under 18 years of age and about 3.3% in adults globally. They contrast these expected levels with administrative diagnostic data from England, where the most recent pre-pandemic figures showed 2.5% prevalence in boys, 0.7% in girls, 0.7% in men, and 0.2% in women in health service records. The gap between expected prevalence and recorded diagnoses suggests many people with ADHD may be living without a diagnosis and without adequate support. The comparison is presented as a mismatch between population-level expectations and what is captured in routine administrative figures.

Service access constraints are also emphasized, with the authors highlighting long waiting times for assessment in the UK. In figures cited in the report, around 27% of children and young people diagnosed with ADHD reported waiting one to two years for assessment, while 14% reported waits of two to three years. The report notes growing demand and pressure on services, including among adults who were not diagnosed in childhood. Taken together, the reported data and narrative describe an access bottleneck in which assessment timelines can extend well beyond a year for a substantial minority.

On diagnostic validity, the authors underscore that there are no biological diagnostic markers for ADHD, and the paper emphasizes the importance of careful and comprehensive clinical assessment. It also notes that misdiagnosis can occur in some cases, including when diagnostic criteria are applied inconsistently, assessments are of low quality, or differential diagnoses are not adequately considered. Despite the absence of biomarkers, the paper reports that field trials found ADHD diagnosis to be among the most reliable mental health diagnoses when clinicians are properly trained and apply standardized criteria. In this account, diagnostic confidence is portrayed as dependent on comprehensive clinical assessment and clinician training rather than biomarker confirmation.

The authors also discuss the broader consequences of untreated ADHD and note that the condition is associated with increased risks of adverse outcomes, including academic failure, suicidal behaviors, substance misuse, accidental injuries, transport accidents, criminality, and mortality. They emphasize that effective treatments exist and are supported by evidence, but that access to care remains uneven.

Finally, the authors are reported to describe proposals including improved funding, expanded workforce training for both specialists and General Practitioners, a more balanced evidence-based public conversation, and consideration of a severity-stratified stepped-care approach as system-level responses to the gaps they describe.

Key Takeaways:

• The authors report that claims of widespread ADHD overdiagnosis in the UK are not supported by published evidence, while unmet diagnostic and treatment needs remain substantial.
• International prevalence estimates (about 5.4% in under-18s and 3.3% in adults) exceed English administrative diagnosis rates, suggesting a gap between expected prevalence and recorded cases.
• The report emphasizes long assessment waits, limited service capacity, and the need for better-funded services, improved clinician training—including for GPs—and severity-stratified care pathways to address unmet need.